Enovis CORP
Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes devices used in reconstructive surgery, rehabilitation, pain management and physical therapy. Its products support care from injury prevention through recovery after surgery or injury and treatment of… From the company’s description.
Over the twelve months to Oct 2, 2026, Enovis CORP reported revenue of $2.31B, up 3.3% from a year earlier, and a net loss of $526.52M. Its operating margin was −20.6%, and operations generated $259.02M in cash. In fiscal 2025, it reported revenue of $2.25B, up 6.7% from fiscal 2024, and a net loss of $1.18B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Enovis CORP does
In the company’s own words
Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes devices used in reconstructive surgery, rehabilitation, pain management and physical therapy. Its products support care from injury prevention through recovery after surgery or injury and treatment of degenerative disease, serving orthopedic specialists and other healthcare professionals as well as retail consumers. Enovis reports two segments. Prevention & Recovery offers orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems, compression garments, electrical stimulators and physical therapy products. Reconstructive provides implants, instruments and enabling technologies for joint replacement, limb reconstruction, and foot and ankle procedures, along with surgeon education and digital tools. The company sells through independent distributors and direct salespeople, and its international operations generated approximately 42% of net sales in 2025, primarily in Europe. Its products address shoulder, hip, knee and extremity reconstruction, as well as injury prevention and at-home therapy.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- LEWISVILLE, TX
- Fiscal year end
- December
- CIK
- 1420800
- SIC
- 3842
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Enovis CORP — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Enovis CORP’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Enovis CORP’s bonds, as funds hold them
Funds report holding 1 issues of Enovis CORP’s debt, $32.50M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.88%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Enovis CORP and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Enovis CORP's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Enovis CORP's last four quarterly filings that the numbers alone won't show?”